Malignant hyperthermia

Denborough, 1960, Anaesthetic deaths in a family, Lancet, ii, 45, 10.1016/S0140-6736(60)92690-8 Kalow, 1970, Metabolic error of muscle metabolism after recovery from malignant hyperthermia, Lancet, ii, 895, 10.1016/S0140-6736(70)92069-6 Ellis, 1971, Halothane-induced muscle contracture as a cause of hyperthermia, Br J Anaesth, 43, 721 Ording, 1988, Diagnosis of susceptibility to malignant hyperthermia in Man, Br J Anaesth, 60, 287, 10.1093/bja/60.3.287 1984, A protocol for the investigation of malignant hyperthermia (MH) susceptibility, Br J Anaesth, 56, 1267, 10.1093/bja/56.11.1267 1985, Laboratory diagnosis of malignant hyperthermia susceptibility (MHS), Br J Anaesth, 57, 1038, 10.1093/bja/57.10.1038 Larach, 1989, Standardisation of the caffeine halothane muscle contracture test, Anaesth Analg, 69, 511, 10.1213/00000539-198910000-00015 Ellis, 1985, Clinical and biochemical aspects of MH, 173 Lopez, 1985, Intracellular ionised calcium concentration in muscles from humans with malignant hyperthermia, Muscle Nerve, 8, 355, 10.1002/mus.880080502 Iaizzo, 1988, Fura-2 detected myoplasmic calcium and its correlation with contracture force in skeletal muscle from normal and malignant hyperthermia susceptible pigs, Pflugers Archiv, 411, 648, 10.1007/BF00580861 Rios, 1987, Involvement of dihydropyridine receptors in excitation-contraction coupling in skeletal muscle, Nature, 325, 717, 10.1038/325717a0 Tanabe, 1988, Restoration of excitation-contraction coupling and slow calcium current in dysgenic muscle by dihydropyridine receptor complementary DNA, Nature, 336, 134, 10.1038/336134a0 Takeshimia, 1994, Excitation-contraction uncoupling and muscular degeneration in mice lacking functional skeletal muscle ryanodine receptor gene, Nature, 369, 556, 10.1038/369556a0 Mickelson, 1988, Abnormal sarcoplasmic reticulum ryanodine receptors in malignant hyperthermia, J Biol Chem, 263, 9310, 10.1016/S0021-9258(19)76541-7 Lai, 1988, Purification and reconstitution of the calcium release channel from skeletal muscle, Nature, 331, 315, 10.1038/331315a0 Foster, 1989, Inositol 1,4,5 trisphosphate phosphatase and malignant hyperthermia in swine, Lancet, ii, 124, 10.1016/S0140-6736(89)90182-7 Foster, 1994, The metabolism of phosphates in malignant hyperpyrexia-susceptible (MHS) porcine skeletal muscle Ellis, 1986, The work of the Leeds Malignant Hyperthermia Investigation Unit, 1971–84, Anaesthesia, 46, 806 Halsall, 1979, Retrospective analysis of anaesthetics received by patients before malignant hyperthermia was recognised, Br J Anaesth, 51, 949, 10.1093/bja/51.10.949 Britt, 1988, Hereditary and epidemiological aspects of malignant hyperthermia, 19 Brownell, 1988, Malignant hyperthermia: relationship to other diseases, Br J Anaesth, 60, 303, 10.1093/bja/60.3.303 Ellis, 1990, Clinical presentation of suspected malignant hyperthermia during anaesthesia in 402 probands, Anaesthesia, 45, 838, 10.1111/j.1365-2044.1990.tb14566.x Larach, 1994, A clinical grading scale to predict malignant hyperthermia susceptibility, Anaesthesiology, 80, 771, 10.1097/00000542-199404000-00008 Leary, 1990, Masseteric muscle spasm as a normal response to suxamethonium, Br J Anaesth, 64, 488, 10.1093/bja/64.4.488 VanDerSpek, 1987, The effect of succinycholine on mouth opening, Anaesthesiology, 67, 459, 10.1097/00000542-198710000-00003 Christian, 1989, Is there a relationship between masseter muscle spasm and malignant hyperthermia, Br J Anaesth, 62, 540, 10.1093/bja/62.5.540 Halsall, 1992, Does postoperative pyrexia indicate malignant hyperthermia susceptibility?, Br J Anesth, 68, 209, 10.1093/bja/68.2.209 Hopkins, 1991, Ryanodine contracture: a potentially specific in vitro diagnostic test for malignant hyperthermia, Br J Anaesth, 66, 611, 10.1093/bja/66.5.611 Lenzen, 1993, Accelerated contractures after administration of ryanodine to skeletal muscle of malignant hyperthermia susceptible patients, Br J Anaesth, 71, 242, 10.1093/bja/71.2.242 Hopkins, 1993, Comparison of in vitro contracture testing with ryanodine, halothane, caffeine in malignant hyperthermia and other neuromuscular disorders, Br J Anaesth, 70, 397, 10.1093/bja/70.4.397 Harriman, 1988, Malignant Hyperthermia Myopathy — a critical review, Br J Anaesth, 60, 309, 10.1093/bja/60.3.309 Halsall, 1992, A review of the MHE Group from European MH Group Lehmann-Horn, 1990, Are myotonias and periodic paralysis associated with susceptibility to malignant hyperthermia?, Br J Anaesth, 65, 692, 10.1093/bja/65.5.692 Lehmann-Horn, 1990, Muscle diseases relevant to the anaesthetist, Acta Anaesthesiol Belg, 41, 113 Heytens, 1992, In vitro contracture tests in patients with various neuromuscular diseases, Br J Anaesth, 68, 72, 10.1093/bja/68.1.72 Isaacs, 1993, False-negative results with muscle caffeine halothane contracture testing for malignant hyperthermia, Anaesthesiology, 79, 5, 10.1097/00000542-199307000-00003 Bridges L R, Halsall P J, Hopkins P M, Ellis F R. Central Core disease and malignant hyperthermia do not always co-exist. (In press). Haan, 1990, Assignment of the gene for central core disease to human chromosome 19, Human Genetics, 86, 187, 10.1007/BF00197703 Kaush, 1991, Evidence for linkage of the central core disease locus to the proximal arm of the human chromosome 19, Genomics, 10, 765, 10.1016/0888-7543(91)90461-M Zhang, 1993, A mutation in the human ryanodine receptor gene associated with central core disease, Nature Genetics, 5, 45, 10.1038/ng0993-46 Quane, 1993, Mutations in the ryanodine receptor gene in CCD and MH, Nature Genetics, 5, 51, 10.1038/ng0993-51 Krivosic-Horber, 1989, MH and neuroleptic malignant syndrome, Beitrage zur Anaesthesiologie and Intensivmedizin, 27, 108 Denborough, 1982, Malignant Hyperthermia and sudden infant deaths, Lancet, ii, 1068, 10.1016/S0140-6736(82)90005-8 Ellis, 1988, Malignant hyperthermia and sudden infant death syndrome, Br J Anaesth, 60, 28, 10.1093/bja/60.1.28 Hopkins, 1991, Evidence for related myopathies in exertional heat stroke and malignant hyperthermia, Lancet, 388, 1491, 10.1016/0140-6736(91)92304-K Hopkins, 1991, Hypermetabolism in arthrogryphosis multiplex congenita, Anaesthesia, 46, 374, 10.1111/j.1365-2044.1991.tb09548.x McPherson, 1981, The King Syndrome. Malignant Hyperthermia, Myopathy and Multiple anomalies, Am J Med Genet, 8, 159, 10.1002/ajmg.1320080206 Harbitz, 1990, Assignment of the Porcine Calcium Release Channel gene, a candidate for the malignant hyperthermia locus to the 6p11 → q21 segment of chromosome 6, Genomics, 8, 243, 10.1016/0888-7543(90)90278-3 Mackenzie, 1990, The human ryanodine reception gene: its mapping to 19q 13.1, placement in a Chromosome 19 linkage group, and exclusion as the gene causing myotonic dystrophy, Am J Hum Genet, 6, 1082 MacLennan, 1990, Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia, Nature, 343, 559, 10.1038/343559a0 McCarthy, 1990, Localisation of the malignant hyperthermia susceptibility locus to human chromosome 19q 12–13.2, Nature, 343, 562, 10.1038/343562a0 Fujii, 1991, Identification of a mutation in the porcine ryanodine receptor that is associated with MH, Science, 253, 448, 10.1126/science.1862346 Gillard, 1992, A substitution of cysteine for orginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia, Genomics, 13, 1247, 10.1016/0888-7543(92)90042-Q 1994 Keating, 1994, Detection of a novel RYR1 mutation in four malignant hyperthermia families, Human molecular Genetics, 3, 1855, 10.1093/hmg/3.10.1855 Deufel, 1991, Two recombinations between malignant hyperthermia susceptibility and human ryanodine receptor in a single family: another gene for MHS?, Human Gene Mapping 11: Cytogenet Cell Genet, 58, 2018 Deufel, 1992, Evidence for genetic heterogeneity of malignant hyperthermia susceptibility, Am J Hum Genet, 50, 1151 Ball, 1993, Genetic linkage analysis of chromosome 19 markers in malignant hyperthermia, Br J Anaesth, 70, 70, 10.1093/bja/70.1.70 Levitt, 1991, Evidence for genetic heterogeneity in malignant hyperthermia susceptibility, Genomics, 11, 543, 10.1016/0888-7543(91)90061-I Isles, 1994, Chromosomal localisation of the genes encoding the subunits of the heart and skeletal muscle L-type voltage dependent calcium channels, CACNLIAI and CACNLIA3: segregation analysis in malignant hyperthermia susceptible families, Thesis Nijmegen, 59 Isles, 1994, Localisation of the gene encoding the submits of the L-type voltage dependant calcium channel (CACNLZA) to the region q11.12–q21.1 of Chromosome 7 and segregation analysis of flanking markers in malignant hyperthermia susceptible (MHS) families, Human Molecular Genetics, 3, 969, 10.1093/hmg/3.6.969 Levitt, 1991, Evidence for the localisation of a malignant hyperthermia susceptible locus (MHS 2) to human chromosome 17q, Genomics, 11, 543, 10.1016/0888-7543(91)90061-I Iles, 1993, Genetic mapping of the B1 and subunits of the human skeletal muscle L-type voltagedependent calcium channels on Chromosome 17q and exclusion as candidate genes for malignant hyperthermia susceptibility, Human Molecular Genetics, 2, 863, 10.1093/hmg/2.7.863 Sudbrak, 1993, Exclusion of malignant hyperthermia susceptibility (MHS) from a putative MHS2 locus on Chromosome 17q and of the α1, β1 and γ subunits of the dihydripyridine receptor calcium channel as candidates for the molecular defect, Human Molecular Genetics, 2, 857, 10.1093/hmg/2.7.857 Sudbrak, 1995, Mapping of a further malignant hyperthermia susceptibility (MHS) locus to chromosome 3q13.1, Am J Hum Genet, 56, 684 Healy, 1991, Diagnosis of susceptibility to malignant hyperthermia with flanking DNA markers, BMJ, 303, 1225, 10.1136/bmj.303.6812.1225 Ellis, 1992, Detecting susceptibility to malignant hyperthermia, BMJ, 304, 791, 10.1136/bmj.304.6830.791